Docetaxel and Carboplatin Versus Docetaxel as Second Line Treatment in Patients With Non-Small-Cell Lung Carcinoma (NSCLC)
This trial will compare the effectiveness of Docetaxel with or without Carboplatin as second line chemotherapy in patients with Non-Small Cell Lung Cancer, who have not been treated previously with Docetaxel.
Non-Small Cell Lung Cancer
DRUG: Docetaxel|DRUG: Carboplatin
Comparison of the overall survival between the two treatment groups, 1 year
Comparison of the objective response rates between the two treatment groups, Objective responses confirmed by CT or MRI (on 3rd and 6th cycle)|Evaluation and comparison of the toxicity between the two treatment groups, Toxicity assessment on each chemotherapy cycle|Measurement and comparison of the health-related quality of life of patients on both treatment groups, Assessment every two cycles
This trial will compare the effectiveness of Docetaxel with or without Carboplatin as second line chemotherapy in patients with Non-Small Cell Lung Cancer, who have not been treated previously with Docetaxel.